Fool.com Analysts Flag Abivax and Viking Therapeutics as Potential Double‑digit Gainers by 2030

Why It Matters

If Abivax secures approval for ob‑efazimod, it could introduce a safer oral option for ulcerative colitis, a disease that affects millions and currently relies on injectable biologics. A successful launch would also demonstrate that clinical‑stage biotech firms can achieve commercial scale without a revenue history, potentially reshaping valuation models for similar companies. Viking’s progress could accelerate the shift toward oral anti‑obesity medicines, expanding treatment access beyond patients comfortable with injections. A breakthrough in this segment would intensify competition, likely driving down prices and spurring innovation across the weight‑loss market. Both scenarios illustrate how late‑stage biotech breakthroughs can generate outsized returns and influence broader therapeutic landscapes.

Key Takeaways

• Fool.com analysts project a 19% CAGR for Abivax and Viking Therapeutics, implying share price doublings by 2030.
• Abivax’s ob‑efazimod achieved a 47.3% response rate in a phase‑3 UC trial; maintenance data due before Q2.
• Viking Therapeutics’ VK2735 is in phase‑3; oral formulation to start phase‑3 by year‑end.
• Abivax’s market cap is €8.44 bn (~$9.8 bn), reflecting high expectations for its pipeline.
• Both companies face competitive pressures—UC biologics for Abivax and major pharma weight‑loss entrants for Viking.

Pulse Analysis

The double‑digit upside forecast for Abivax and Viking underscores a broader market trend: investors are rewarding biotech firms that can articulate clear, near‑term pathways to revenue despite the inherent risk of clinical failure. Historically, the biotech sector has been dominated by companies with at least one marketed product; the willingness to assign a $9.8 billion valuation to a pre‑revenue firm like Abivax signals a shift toward valuation based on pipeline potential rather than cash flow. This shift is amplified by the growing appetite for oral therapies, as seen in Viking’s strategy to diversify beyond injectable GLP‑1 analogs.

From a competitive standpoint, both firms are betting on differentiation. Ob‑efazimod’s non‑immunosuppressive profile could carve out a niche in a market saturated with biologics that carry infection risks. Meanwhile, Viking’s dual‑formulation approach may capture patients who prefer oral dosing, a segment that recent GLP‑1 oral approvals have validated. If either company falters, the market’s appetite for high‑risk, high‑reward biotech bets could contract, prompting a re‑pricing of similar speculative stocks.

Looking forward, the next 12‑18 months will be decisive. Positive data releases could trigger a cascade of analyst upgrades, institutional buying, and higher trading volumes, reinforcing the projected growth trajectory. Conversely, any adverse trial outcomes would likely precipitate sharp sell‑offs, given the thin margin for error in clinical‑stage valuations. Stakeholders should monitor the timing of Abivax’s maintenance readout and Viking’s phase‑3 results as leading indicators of whether the 2030 double‑digit targets remain realistic.